Arch Therapeutics, Inc.

Equities

ARTH

US03939W2089

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 15:26:25 2024-07-15 EDT			5-day change	1st Jan Change
0.6244 ^USD	-13.27%		-40.53%	-91.38%

06-30	Arch Therapeutics, Inc. announced that it has received $5.058 million in funding from Drake Partners, LLC, Oasis Capital, LLC	CI
06-12	Arch Therapeutics, Inc. announced that it has received $0.15 million in funding	CI

Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019

January 30, 2020 at 01:23 pm

Arch Therapeutics, Inc. announced earnings results for the first quarter ended December 31, 2019. For the first quarter, the company announced operating loss was USD 1.619 million compared to USD 1.767 million a year ago. Net loss was USD 1.659 million compared to USD 2.600 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.

Latest news about Arch Therapeutics, Inc.

Arch Therapeutics, Inc. announced that it has received $5.058 million in funding from Drake Partners, LLC, Oasis Capital, LLC	06-29	CI
Arch Therapeutics, Inc. announced that it has received $0.15 million in funding	06-11	CI
Arch Therapeutics, Inc. announced that it has received $1.85 million in funding	05-14	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-09	CI
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)	05-06	CI
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-20	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	02-15	CI
Arch Therapeutics, Inc. to Present AC5®? Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)	11-02	CI
Arch Therapeutics, Inc. Provides Commercialization Update on the First Product, AC5 Advanced Wound System	23-09-13	CI
Arch Therapeutics, Inc. announced that it has received $2.560063 million in funding	23-08-30	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-11	CI
Arch Therapeutics, Inc. announced that it expects to receive $1.850001 million in funding	23-07-06	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-23	CI
Arch Therapeutics to Present AC5(R) Advanced Wound System At 2023 Symposium on Advanced Wound Care	23-04-25	CI
Arch Therapeutics, Inc. Announces Dedicated HCPCS Billing Code for its Advanced Wound System Now in Effect	23-04-05	CI
Arch Therapeutics' AC5(R) Advanced Wound System Receives Dedicated HCPCS Billing Code from the Centers for Medicare & Medicaid Services	23-03-09	CI
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of Ac5® Advanced Wound System in Government Facilities	23-03-07	CI
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-14	CI
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System	23-01-18	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-28	CI
Arch Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-12-27	CI
Arch Therapeutics Announces First Shipments of Ac5® Advanced Wound System Under New Reimbursement Support Program	22-09-23	CI
Arch Therapeutics, Inc. Launches Multi-Site Clinical Study for AC5® Advanced Wound System	22-09-07	CI
Arch Therapeutics, Inc. Submits Application to Centers for Medicare and Medicaid Services for Ac5® Advanced Wound System	22-09-01	CI
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-11	CI

Chart Arch Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Companyâs flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Medical Devices & Implants

	1st Jan change	Capi.
ARCH THERAPEUTICS, INC.	-91.38%	2.78M
SMITH & NEPHEW PLC	-0.74%	12.12B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-20.75%	6.91B
GLAUKOS CORPORATION	+54.95%	6.72B
INSPIRE MEDICAL SYSTEMS, INC.	-31.88%	4.12B
AXONICS, INC.	+9.03%	3.46B
ENOVIS CORPORATION	-20.14%	2.45B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-19.75%	1.88B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-29.10%	1.57B
DOUBLE MEDICAL TECHNOLOGY INC.	-37.42%	1.45B

Medical Devices & Implants